Ketamine's Addiction Potential: A Realistic Assessment
Ketamine is classified as a Schedule III controlled substance in the United States, meaning the DEA has determined it has moderate to low potential for physical and psychological dependence relative to Schedule I and II drugs. This classification is based on decades of clinical observation, animal studies, and the experience of recreational users.
Prescribing ketamine therapeutically means engaging with a substance that has real, documented abuse potential. Dismissing this concern ("it's therapeutic, so dependence isn't possible") is as incorrect as overcounting it ("this is just another dangerous addictive drug"). A nuanced, evidence-based understanding serves patients and providers best. The broader safety profile of sublingual ketamine provides additional context.
The Spectrum of Ketamine-Related Problems
Ketamine use problems exist on a spectrum:
Non-problematic therapeutic use: Patient uses ketamine exactly as prescribed within a structured therapeutic context, experiences benefit, and maintains appropriate boundaries around use. This describes the vast majority of therapeutic ketamine patients.
Psychological dependence: Patient develops a reliance on ketamine sessions that extends beyond clinical need — using for emotional regulation, comfort-seeking, or anxiety relief outside the therapeutic framework. The desire to use is persistent and difficult to voluntarily restrict.
Physical dependence (rare at therapeutic doses): Some degree of neuroadaptation may occur with long-term use, such that discontinuation produces temporary withdrawal symptoms. At therapeutic dosing frequencies, this is not well-documented clinically, but patients who have used ketamine very frequently for extended periods may experience rebound symptoms upon abrupt discontinuation. Our article on long-term safety data discusses what we currently know about extended use.
Ketamine use disorder: A diagnosable substance use disorder characterized by compulsive use despite negative consequences, loss of control over use, and prioritization of use over other life functions. This is documented in recreational users and, rarely, in patients who escalate therapeutic use.
Mechanisms of Ketamine's Abuse Liability
Dopamine Reward Pathway
Ketamine activates dopamine release in the nucleus accumbens and prefrontal cortex — the same circuits involved in the rewarding effects of other addictive drugs. This dopamine release is associated with the euphoric, dissociative "high" that recreational users seek.
In therapeutic use, this same mechanism may contribute to the sense of relief and wellbeing that makes ketamine sessions feel positive and perhaps motivating to repeat. The distinction between therapeutic positive reinforcement and addictive positive reinforcement is one of context, dose, and pattern — not a categorical neurobiological difference.
NMDA Receptor Tolerance
With repeated ketamine use, NMDA receptors may undergo compensatory upregulation — the system adjusts to restore baseline function in the presence of persistent NMDA blockade. This is a form of tolerance: over time, the same dose produces less NMDA blockade and less subjective effect, potentially motivating dose escalation.
This tolerance mechanism is more relevant to daily or near-daily use than to once- or twice-monthly therapeutic protocols.
Real-World Prevalence of Ketamine Dependence in Therapeutic Patients
The question most patients ask: "How likely am I to become addicted if I use ketamine therapeutically?"
Honest answer: the specific incidence in therapeutic outpatient populations is not well-characterized by published studies. What we can say:
- Clinical impression: Most experienced ketamine prescribers report that genuine dependence in therapeutic patients on standard protocols is uncommon — far less common than the popular concern about it suggests.
- Risk factors that increase vulnerability: Personal history of substance use disorder, current substance use disorder, family history of addiction, borderline personality features, and prior traumatic attachment to substances are all risk factors.
- High-risk use patterns: More frequent sessions, escalating doses, and use outside structured therapeutic contexts (impulsive use for distress relief) are warning signs.
The risk is real but manageable with appropriate patient selection, protocol structure, and monitoring.
Warning Signs of Problematic Use
Patients and providers should monitor for:
Dose escalation without clinical justification: Repeatedly requesting dose increases, using more than one troche per session, or difficulty functioning within prescribed parameters.
Increasing session frequency: Using more sessions per week or month than prescribed, shortening intervals between sessions without clinical justification.
Use outside therapeutic framework: Taking a troche impulsively when emotionally distressed rather than within a planned, structured session context.
Craving and preoccupation: Thinking about the next ketamine session frequently, feeling distress when sessions are delayed, planning life around ketamine availability.
Using for emotional regulation: Specifically seeking ketamine to manage acute emotional states rather than as a structured therapeutic intervention.
Continued use despite adverse consequences: Using despite knowing that urinary, cognitive, or relationship problems may be related to ketamine use.
Dishonesty with the prescriber: Minimizing concerns, hiding extra use, or not reporting adverse effects to avoid losing the prescription.
Safeguards in Responsible Programs
Well-designed ketamine therapy programs incorporate structural safeguards against misuse:
Controlled Prescription Quantities
Many responsible providers prescribe only enough troches for 2 to 4 sessions at a time (not 30 days at once). This limits stockpiling, prevents diversion, and creates natural accountability check-ins.
Secure Storage Requirements
Patients should be instructed to store troches in a locked box or secure location. Preventing easy access reduces impulsive use patterns.
Structured Session Framework
Sessions should occur within a defined therapeutic structure — specific day, specific preparation, specific setting. Troches should not be used spontaneously or outside this structure. Providers who reinforce this structure are building in behavioral safeguards.
Regular Use Review
At every follow-up, the provider should ask directly about:
- Are you using exactly as prescribed?
- Have you felt the urge to use more often than prescribed?
- Have you used outside the planned session structure?
These are not gotcha questions — they are clinical monitoring questions. Honest answers guide appropriate clinical responses.
Dose Management
Providers who maintain doses at the minimum effective level, resist casual escalation requests, and have explicit criteria for dose adjustment are building structural safeguards against escalation dynamics.
How to Talk to Your Provider About Dependence Concerns
If you notice warning signs in yourself, tell your provider. This is not a reason to be ashamed; it is clinical information that your provider needs to adjust the treatment plan.
Useful phrases:
- "I've been thinking about ketamine sessions more than I think is typical. I wanted to flag this."
- "I've felt an urge to use my troche outside of my scheduled session twice this month. That concerns me."
- "I'm worried I'm using ketamine as emotional avoidance rather than as a therapeutic tool. Can we discuss this?"
A provider who responds to this kind of honesty with judgment or threat of prescription withdrawal is not providing patient-centered care. A good provider will appreciate the self-awareness and work collaboratively on it.
When to Seek Addiction Medicine Assessment
If warning signs are present that you or your provider cannot adequately address within the standard ketamine therapy framework, consider consultation with an addiction medicine specialist. This is not a punishment or failure — it is appropriate escalation of care for a complex clinical situation.
An addiction medicine specialist can:
- Assess the degree of dependence using validated instruments
- Provide a plan for managing use while maximizing therapeutic benefit
- Evaluate whether a brief ketamine pause or taper is appropriate
- Ensure that the overall care plan balances psychiatric benefit against addiction risk
Key Takeaways
- Ketamine has documented abuse liability; psychological dependence is possible and documented in therapeutic patients, though uncommon in well-managed programs.
- Risk factors include personal and family history of substance use disorders, emotional dysregulation, and use outside structured therapeutic contexts.
- Warning signs: dose escalation, increasing frequency, craving, impulsive use, dishonesty with provider.
- Safeguards: controlled quantities, structured session framework, secure storage, honest provider-patient communication.
- Discuss any concerns with your provider honestly — this is clinical information, not a confession.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- FDA: Approved Drug Products — U.S. Food and Drug Administration searchable database of approved drug products and therapeutic equivalents
- SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service
Share